Karyopharm (KPTI) announced that Kristin Abate, the company’s Vice President, Accounting, Corporate Controller and Assistant Treasurer, has been appointed Vice President, Chief Accounting Officer, and Assistant Treasurer, effective November 20. Abate, who has also served as interim principal financial officer and interim principal accounting officer since November 6, has been designated as the company’s principal accounting officer, effective November 20, 2024. Abate will continue to serve as the company’s interim principal financial officer. Abate has been employed by the company since July 2019 in a variety of roles with increasing seniority, most recently as its VP, Accounting, Corporate Controller and Assistant Treasurer. Prior to joining the company, Abate worked in various roles as a public accountant from 2007 to July 2019 at PricewaterhouseCoopers.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on KPTI:
- Karyopharm price target raised to $5 from $4 at Piper Sandler
- Karyopharm Therapeutics Inc. Reports Q3 2024 Earnings
- Karyopharm reports Q3 EPS (26c), consensus (27c)
- Karyopharm narrows 2024 revenue view to $145M-$155M from $145M-$160M
- Karyopharm Therapeutics Updates Phase 3 SENTRY Trial
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
